ELVNHealthcare · BiotechnologyELVN Stock Forecast: Enliven Therapeutics, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Enliven Therapeutics, Inc. hold a median 12-month price target of $64 — +10.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
ELVN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Enliven Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (36): The company has been issuing shares or taking on financing, diluting existing holders.
Size (27): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Enliven Therapeutics, Inc. — and when they’d sell — is the membership.
ELVN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $59 → $67 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $56 → $64 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2026 | Stifel | Maintains | Buy | — |
| 29 June 2026 | Jones Trading | Maintains | Buy | — |
| 9 June 2026 | Stifel | Initiates | Buy | — |
| 2 June 2026 | Mizuho | Maintains | Outperform | — |
| 8 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 2 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 June 2025 | Baird | Maintains | Outperform | — |
| 16 June 2025 | Goldman Sachs | Initiates | Buy | — |
| 16 May 2025 | Jones Trading | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Dec 2024 | BTIG | Initiates | Buy | — |
| 15 Nov 2024 | Baird | Maintains | Outperform | — |
| 31 Oct 2024 | Jones Trading | Initiates | Buy | — |
| 1 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELVN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Enliven Therapeutics, Inc. (ELVN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −29.9×
- Price / sales
- —
- Price / book
- 7.4×
- EV / EBITDA
- −25.0×
Cheaper than 97% of US stocks
Cheaper than 14% of US stocks
Cheaper than 90% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −26.6%
- Return on assets
- −18.9%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ELVN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELVN appears on the weeks it earns a place.
Frequently asked questions about ELVN stock
What is the ELVN stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Enliven Therapeutics, Inc. have a median 12-month price target of $64, with estimates ranging from $59 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELVN stock a buy right now?
Of the 10 analysts covering Enliven Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enliven Therapeutics, Inc. 78 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELVN?
As at 1 Aug 2026, Enliven Therapeutics, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will ELVN stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +10.3% from the last close, and Ticker Nerd's factor model ranks Enliven Therapeutics, Inc. 78 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELVN stock forecast for 2030?
No analyst covering Enliven Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $59 to $80 over the next 12 months.
How has ELVN stock performed over the past year?
Enliven Therapeutics, Inc. returned +209.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases.
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.
CEO Mr. Richard A. Fair M.B.A. · 61 employees · United States · https://www.enliventherapeutics.com